Evidence map›Paper›PMID 34117331›Full record

ArticleScientific reports2021

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches.

Samira Sanami, Fatemeh Azadegan-Dehkordi, Mahmoud Rafieian-Kopaei, Majid Salehi, Maryam Ghasemi-Dehnoo, Mehran Mahooti, Morteza Alizadeh, Nader Bagheri

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Frontiers in oncology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Samira SanamiDepartment of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Fatemeh Azadegan-DehkordiCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Mahmoud Rafieian-KopaeiMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Majid SalehiDepartment of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Maryam Ghasemi-DehnooMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Mehran MahootiDepartment of Biotechnology, Iranian Research Organization for Science and Technology, Tehran, Iran.
Morteza AlizadehDepartment of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. mor1361@gmail.com.
Nader BagheriCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. n.bagheri1985@gmail.com.
Shahrekord University of Medical Sciences · IRShahroud University of Medical Sciences · IRIranian Research Organization for Science and Technology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer, caused by human papillomavirus (HPV), is the fourth most common type of cancer among women worldwide. While HPV prophylactic vaccines are available, they have no therapeutic effects and do not clear up existing infections. This study aims to design a therapeutic vaccine against cervical cancer using reverse vaccinology. In this study, the E6 and E7 oncoproteins from HPV16 were chosen as the target antigens for epitope prediction. Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) epitopes were predicted, and the best epitopes were selected based on antigenicity, allergenicity, and toxicity. The final vaccine construct was composed of the selected epitopes, along with the appropriate adjuvant and linkers. The multi-epitope vaccine was evaluated in terms of physicochemical properties, antigenicity, and allergenicity. The tertiary structure of the vaccine construct was predicted. Furthermore, several analyses were also carried out, including molecular docking, molecular dynamics (MD) simulation, and in silico cloning of the vaccine construct. The results showed that the final proposed vaccine could be considered an effective therapeutic vaccine for HPV; however, in vitro and in vivo experiments are required to validate the efficacy of this vaccine candidate.

Indexed as

Cancer VaccinesComputational BiologyEpitopesFemaleHumansImmunogenicity, VaccineMolecular Docking SimulationOncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus VaccinesRepressor ProteinsT-Lymphocytes, CytotoxicT-Lymphocytes, Helper-InducerUterine Cervical NeoplasmsCancer VaccinesE6 protein, Human papillomavirus type 16Epitopesoncogene protein E7, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus VaccinesRepressor Proteins

Identifiers

PMID34117331
PMCPMC8196015
OpenAlexW3168092052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.